Table 1. Baseline clinical and molecular characteristics among patients that are MET protein over-expression, MET/T790M coexistence, and T790M positive.
| Variable category | MET positive (n=42) | MET/T790M positive (n=14) | T790M positive (n=72) | P |
|---|---|---|---|---|
| Age (median, range) | 56 (32-78) | 55(21-78) | 54.5 (38-76) | |
| <65 ≥65 |
30(71.4%) 12(28.6%) |
12(85.7%) 2(14.3%) |
60(83.3%) 12(16.7%) |
0.262 |
| Gender Male Female |
16(38.1%) 26 (61.9%) |
5(35.7%) 9(64.3%) |
30(41.7%) 42(58.3%) |
0.881 |
| Smoking status Smoker Nonsmoker |
34(81.0%) 8 (19.0%) |
12(85.7%) 2(14.3%) |
53(73.6%) 19(26.4%) |
0.486 |
| ECOG PS ≤1 ≥2 |
41(97.6%) 1 (2.4%) |
14(100.0%) 0(0.0%) |
69(95.8%) 3(4.2%) |
0.675 |
| Histology Adenocarcinoma Squamous Adenosquamous |
41(97.6%) 0 (0.0%) 1(2.4%) |
13 (92.9%) 1(7.1%) 0(0.0%) |
68(94.4%) 2(2.8%) 2(2.8%) |
0.585 |
| EGFR mutation DEL L858R Others |
25(59.5%) 16(38.1%) 1(2.4%) |
11(78.6%) 2 (14.3%) 1(7.1%) |
51(70.8%) 21(29.2%) 0(0.0%) |
0.141 |
| EGFR TKIs Gefitinib Erlotinib Other EGFR-TKI |
20(47.6%) 21 (50.0%) 1(2.4%) |
7 (50.0%) 7 (50.0%) 0(0.0%) |
43(59.7%) 29(40.3%) 0(0.0%) |
0.479 |
ECOG PS, Eastern Cooperative Oncology Group performance status;
EGFR, epidermal growth factor receptor;